OBJECTIVES: Gastric cancer is the most common malignant tumour in Japan. Because gastric cancer metastases to the lung generally occur as lymphangitic carcinomatosis or numerous lesions, metastasectomy is rarely indicated. Therefore, the role of resectable pulmonary metastasectomy in gastric cancer is still unclear. The objective of this study was to determine the surgical outcomes and prognostic factors for survival after pulmonary resection of resectable metastatic gastric cancer.
INTRODUCTION
There have been many studies reporting on the surgical indications for various types of metastatic tumours. In selected patients, surgical resection is an effective treatment for pulmonary metastasis [1] [2] [3] [4] . While gastric cancer is one of the most common malignant tumours, pulmonary metastases often present as lymphangitic carcinomatosis or numerous lesions [5, 6] , which are often unresectable. The prognosis for metastatic gastric cancer is poor. Recently, Kong et al. revealed that the median survival after diagnosis of pulmonary metastasis was 4 (0-67) months [6] . The 5-year survival of patients with unresected or metastatic gastric cancer who were treated with chemotherapy alone was reported to be only 2-4% [7, 8] . On the other hand, there have been a small number of case reports of long-term survival in patients with resectable pulmonary metastases from gastric cancer who underwent metastasectomy.
However, there has been no large-scale study investigating lung metastasectomy performed for patients with resectable metastatic gastric cancer.
The purpose of this study was to examine the outcomes and prognostic factors affecting survival after surgery for resectable pulmonary metastasis from gastric cancer. We retrospectively reviewed the records of patients who underwent surgical treatment for pulmonary metastases from gastric cancers. The data were prospectively collected from the database of the Metastatic Lung Tumor Study Group of Japan.
resection. To date, 25 institutions have joined the group, and 3831 cases were registered from 1980 to 2011. The following parameters were collected: gender, age, primary tumour histology, stage of primary tumour, treatment for the primary tumour, date of primary surgery, type of surgery, curability, date of metastasis, disease-free interval (DFI), side on which metastases occurred, maximum lesion size, number of resected metastases, date of metastasectomy, other treatments, sites of recurrence and follow-up. The surgical indications and procedures were determined at each institution. Lymph node dissection was not routinely performed and was at the discretion of each institution. The DFI was calculated from the date of the initial treatment for the primary tumour to the date of diagnosis of pulmonary metastasis. The ethics committees of the affiliated institutions approved this database study and waived the need for informed consent from patients, as long as patient data remained anonymous.
Between March 1980 and March 2011, of the 3831 patients registered in the database, 58 patients (1.5%) underwent resection of pulmonary metastases from gastric cancers. Because of incomplete data, 7 patients were excluded from the study, resulting in 51 patients to be examined. Since we investigated the surgical outcomes and prognostic factors of pulmonary metastases from gastric cancers, we examined the survival after pulmonary metastasectomy for the end-point of the study. The date of pulmonary resection was defined as the starting point. Postoperative followup was performed at the discretion of each institution.
Statistical analysis
Overall survival was analysed using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards regression analysis was used to evaluate potential prognostic factors. The data were analysed using version 5.0.1 of the JMP software package (SAS Institute Inc., Cary, NC). A P-value < 0.05 was considered statistically significant.
To investigate the cut-off value of DFI, we performed receiver operating characteristic (ROC) curve analysis. The ROC curve and Youden index identified an optimal cut-off value for DFI and survival [9, 10] . ROC curve analysed using version 5.0.1 of the JMP software package (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics are listed in Table 1 . Regarding chemotherapy after pulmonary metastasectomy, 18 patients received chemotherapy after surgery, while 10 patients did not. However, data for postoperative chemotherapy were not available in the remaining 23 patients. While 3 patients had liver metastasis, one of them was treated by surgical resection for it, and the other two received other non-surgical treatments. Follow-up times after pulmonary metastasectomy ranged from 0 to 154 months (median, 18 months). Recurrences after metastasectomy were found in 21 of 51 patients (41%) ( Table 2 ). Seven cases were considered incomplete resections because of contralateral pulmonary metastasis or metastasis to other organs. The time to recurrence after pulmonary metastasectomy ranged from 0 to 29 months (median, 6 months). While the 30-day operative mortality rate was 0%, 2 patients died in the hospital (4%), 1 died of pneumonia 50 days after surgery and the other of empyema with bronchopleural fistula 81 days after surgery.
The overall 5-year survival rate after pulmonary metastasectomy was 28% (Fig. 1) . The median survival time was 29 months. The prognostic significance of the following clinical factors was assessed by univariate analysis: gender, age, disease free interval (DFI), metastases in other organs, surgical procedures (lobectomy or not), the number of pulmonary metastases (one or multiple), bilateral pulmonary metastases, maximum lesion size and incomplete resection (Table 3 ). According to a review by Kemp et al., all of the long-term survivors after pulmonary metastasectomy had DFIs longer than 12 months [11] . Therefore, we used a DFI cut-off value of 12 months for analysis. Table 4 presents the results of multivariate analyses, which also showed that a DFI of <12 months was a poor prognostic factor. The survival curves for DFIs are shown in Fig. 2 . The 5-year survival rate of 43 patients with DFIs ≥12 months was 31%, whereas survival of the remaining 8 patients with DFIs <12 months did not extend to 5 years. The 2-year survival rate for patients with DFIs ≥12 months was 73% and for patients with DFIs <12 months it was 17% (P < 0.01). Moreover, we investigated the other DFI cut-off values. DFI cut-off values of 24 and 36 months were not significant in overall survival (Fig. 2) . To determine the more appropriate cut-off value of DFI, the patients were also subdivided into two cohorts using receiver operating characteristic (ROC) curve analysis. While the ROC curve identified an optimal DFI cut-off value of 68 months for overall survival, the area under the curve was 0.51.
DISCUSSION
Although gastric cancer is one of the common malignant tumours in Japan, patients with resectable pulmonary metastasis from gastric cancer are rare. While the 2009 annual report from the registry of the Japanese Association for Thoracic Surgery listed 6248 patients who had undergone pulmonary metastasectomy, there was no specific information on the number of patients who underwent surgery for metastatic gastric cancer [12] . Of 276 consecutive patients undergoing pulmonary metastasectomy that were reported by Robert et al., there was only 1 patient with metastasis from gastric cancer (0.4%) [13] . Kanemitsu et al. reported that 22 of 3076 (0.7%) patients with gastric cancer had metastases only in the lung, and only 4 of 3076 (0.1%) patients who underwent curative resection for gastric cancer underwent pulmonary resection [14] . To our knowledge, our study with 51 patients is the largest one ever reported. In a literature review, Kemp et al. summarized 43 patients who underwent metastasectomy for pulmonary metastases from gastric cancer. The overall 5-year survival rate after metastasectomy was 33%, and the median survival time was 29 months [11] . They also reported that 15 of 43 (35%) patients were alive without disease at a median follow-up of 23 months. Although their results might have been affected by publication bias, our findings were similar; in our study, the overall 5-year survival was 28% and the median survival was 29 months. Our findings, along with recent case reports of patients with long-term survival [15, 16] , suggest that selected patients with metastatic gastric cancer may achieve long-term survival.
Our study found that a DFI with a cut-off value of 12 months was the only significant prognostic factor in patients undergoing metastasectomy for pulmonary metastases from gastric cancer. None of the patients with a DFI of <12 months survived >5 years. While Kemp et al. did not find that a DFI of 12 months was significant [11] , their report might have the problem of publication bias, i.e. their report was the result of reviewing literatures, whereas our data were from one study group.
A large retrospective study from the International Registry of Lung Metastases that analysed patients with pulmonary metastases from various organs found that independent prognostic factors for survival included a DFI <36 months and >1 metastasis [2] . Therefore, DFI appears to be a significant prognostic factor for gastric cancers, as well as other types of tumours. However, Robert et al. reported that survival after pulmonary metastasectomy for various tumours was not associated with DFI, and showed that tumour histology and the number of resected metastases were significant prognostic factors [13] . In the present paper, radicality was not a statistical significant risk factor. Although our database lacked enough information, chemotherapy or other treatments might improve the survival of incomplete cases.
This study has the following limitations: (1) The study prospectively collected and retrospectively investigated data accruing over 28 years. During this period, diagnostic procedures and chemotherapy have improved significantly; (2) There may have been selection bias, because the patients enrolled in our study were selected as surgical candidates; (3) The number of patients was small, so our study lacks statistical power; (4) The biggest problem with this study is the heterogeneity of the study population. Since these data collected from 25 institutions and these cases were referral patients, we could not obtain enough information on how many patients had other therapies. The GYMSSA trial by the National Cancer Institute in the United States, a prospective randomized trial for patients with metastatic gastric cancer that compares two therapeutic approaches, gastrectomy with metastasectomy plus systemic chemotherapy (GYMS) vs systemic chemotherapy alone (SA), is now in progress [17] . This new study should provide stronger evidence than the current retrospective data.
In conclusion, because of the small sample size and other limitations, the findings of this study may not provide conclusive results. However, we analysed outcomes of the largest number of patients ever reported, who underwent metastasectomy of resectable pulmonary metastases from gastric cancer, and identified the prognostic factors for survival. We believe that pulmonary metastasectomy should be considered for patients with DFIs of longer than 12 months.
